SCHEMBL24944993

SCHEMBL24944993

COc1nc(Nc2ccc(CN3CCOCC3)cc2F)c(C(N)=O)nc1-c1cncc2c1ncn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 3/20 0.40
▸ CSF1R P07333 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ PIK3CA P42336 3/20 0.36
▸ PIK3CD O00329 3/20 0.36
▸ PIK3R1 P27986 2/20 0.36
▸ PIK3CB P42338 2/20 0.36
▸ PIK3CG P48736 2/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ ALK Q9UM73 1/20 0.36
▸ CCNC P24863 1/20 0.36
▸ CDK8 P49336 1/20 0.36
▸ KCNH2 Q12809 2/20 0.36
▸ IGF1R P08069 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ GRM2 Q14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173398 0.94 LRRK2 (0.40) LRRK2CSF1RJAK2JAK1TYK2
SCHEMBL30206021 0.94 LRRK2 (0.40) LRRK2CSF1RJAK2JAK1TYK2
SCHEMBL24944783 0.90 LRRK2 (0.41) LRRK2CSF1RJAK2JAK1TYK2
SCHEMBL24944376 0.88 LRRK2 (0.35) LRRK2CSF1RJAK2JAK1TYK2
SCHEMBL30206173 0.88 LRRK2 (0.35) LRRK2CSF1RJAK2JAK1TYK2
Formic Acid SCHEMBL29173332 0.88 LRRK2 (0.39) LRRK2CSF1RJAK2JAK1TYK2
Formic Acid SCHEMBL30205467 0.88 LRRK2 (0.39) LRRK2CSF1RJAK2JAK1TYK2
SCHEMBL29173386 0.86 LRRK2 (0.43) LRRK2JAK2JAK1TYK2JAK3
SCHEMBL30206109 0.86 LRRK2 (0.43) LRRK2JAK2JAK1TYK2JAK3
SCHEMBL24944786 0.83 IKBKE (0.38) EGFRALKGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP claimed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN claimed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback